Explore Business Standard
Gland Pharma on Wednesday said it has received approval from the US health regulator for a generic medication to treat conditions related to high pressure in the eye. The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application for Latanoprostene Bunod Ophthalmic Solution, (0.024 per cent), the drug firm said in a statement. The company's product is bioequivalent and therapeutically equivalent to Bausch and Lomb, Inc's Vyzulta ophthalmic solution, it added. The product is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The company is the exclusive first-to-file and is eligible for 180 days of generic drug exclusivity, Gland Pharma said. According to IQVIA, the product had sales of around USD 171 million in the US for the 12 months ending February 2025. Shares of Gland Pharma on Wednesday ended 1.04 per cent down at Rs 1,398.35 apiece on the BSE.
As the market for leadless pacemakers grows in India, doctors point out definite advantages of the technology for heart disease patients but also call for more data and analyses on its long-term effects. At the same time, researchers have written about the lack of a national registry tracking pacemaker implants, including conventional ones. A pacemaker helps a heart patient control an irregular heartbeat. In November, Abbott, the US-based healthcare and medical devices company, introduced the AVEIR VR single-chamber ventricular leadless pacemaker in India for treating patients having slow heart rhythms. The device has been approved by the Central Drugs Standard Control Organization, Abbott said in a statement. The AVEIR VR device is implanted directly into the heart's right lower chamber (ventricle) through a "minimally invasive, catheter-based procedure from the groin", thereby requiring no surgical cuts to the chest or wires, it said. Doctors consider a 'leadless' pacemaker an
U.S. deaths fell last year, and COVID-19 dropped to the nation's No. 4 cause, the Centers for Disease Control and Prevention reported Thursday. COVID-19 deaths trailed those caused by heart disease, cancer and injuries such as drug overdoses, motor vehicle fatalities and shootings. In 2020 and 2021, only heart disease and cancer were ahead of the coronavirus. U.S. deaths usually rise year-to-year, in part because the nation's population has been growing. The pandemic accelerated that trend, making 2021 the deadliest in U.S. history, with more than 3.4 million deaths. But 2022 saw the first drop in deaths since 2009. The 2022 tally was about 3.3 million a 5 per cent decline from 2021 but still much higher than in the years before the pandemic. The CDC cautioned that last year's numbers are preliminary and may change a little after further analysis. Coronavirus-associated death rates fell for nearly all Americans. The virus was deemed the underlying cause of about 187,000 U.S. death